To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL
NCT07143929 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2025-08-27
Summary
To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed PTCL.
Conditions
- CD7 Positive R/R PTCL
Interventions
- DRUG
-
CAR-T
autologous CD7-targeted CAR-T cells, single injection
Sponsors & Collaborators
-
Peking University People's Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-08-18
- Primary Completion
- 2026-07-31
- Completion
- 2027-12-31
Countries
- China
Study Locations
More Related Trials
-
An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma
NCT07344818 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
NCT06180174 ·Status: RECRUITING ·Phase: PHASE1
-
CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors
NCT04702841 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma
NCT04812691 ·Status: COMPLETED ·Phase: PHASE1
-
PD1-CD19-CART in Patients With r/r B-cell Lymphoma
NCT04213469 ·Status: COMPLETED ·Phase: NA
-
Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
NCT07164560 ·Status: RECRUITING ·Phase: PHASE1
-
CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies
NCT05454241 ·Status: COMPLETED ·Phase: PHASE2
-
CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma
NCT04237428 ·Status: UNKNOWN ·Phase: NA
-
CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
NCT02965092 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies
NCT04823091 ·Status: UNKNOWN ·Phase: PHASE1
-
Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma
NCT02992834 ·Status: UNKNOWN ·Phase: PHASE4
-
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma
NCT05020392 ·Status: UNKNOWN ·Phase: PHASE3
-
Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma
NCT03540303 ·Status: UNKNOWN ·Phase: PHASE1
-
Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
NCT03344367 ·Status: UNKNOWN ·Phase: PHASE1
-
CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
NCT03559439 ·Status: UNKNOWN ·Phase: PHASE1
-
CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors
NCT06720324 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Study on the Safety and Efficacy of CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies
NCT07345780 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
NCT02742727 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL
NCT05554575 ·Status: UNKNOWN ·Phase: PHASE1
-
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies
NCT04008394 ·Status: UNKNOWN ·Phase: PHASE1
-
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
NCT04782193 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
NCT06316427 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies
NCT03262298 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies
NCT04007978 ·Status: UNKNOWN ·Phase: PHASE1
-
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
NCT04718883 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2